|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Disopyramide#Adverse Reactions]] |
| {{Disopyramide}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Adverse Reactions==
| |
| | |
| The adverse reactions which were reported in Norpace clinical trials encompass observations in 1,500 patients, including 90 patients studied for at least 4 years. The most serious adverse reactions are hypotension and congestive heart failure. The most common adverse reactions, which are dose dependent, are associated with the anticholinergic properties of the drug. These may be transitory, but may be persistent or can be severe. Urinary retention is the most serious anticholinergic effect.
| |
| | |
| The following reactions were reported in 10% to 40% of patients:
| |
| | |
| '''Anticholinergic''': dry mouth (32%), urinary hesitancy (14%), [[constipation]] (11%)
| |
| | |
| The following reactions were reported in 3% to 9% of patients:
| |
| | |
| '''Anticholinergic''': blurred vision, dry nose/eyes/throat
| |
| | |
| '''Genitourinary''': [[urinary retention]], urinary frequency and urgency
| |
| | |
| '''Gastrointestinal''': [[nausea]], pain/bloating/gas
| |
| | |
| '''General''': [[dizziness]], general fatigue/muscle weakness, headache, [[malaise]], [[aches]]/[[pains]]
| |
| | |
| The following reactions were reported in 1% to 3% of patients:
| |
| | |
| '''Genitourinary''': impotence
| |
| | |
| '''Cardiovascular''': [[hypotension]] with or without [[congestive heart failure]], increased [[congestive heart failure]] (see Warnings), cardiac conduction disturbances (see Warnings), [[edema]]/weight gain, shortness of breath, [[syncope]], [[chest pain]]
| |
| | |
| '''Gastrointestinal''': [[anorexia]], [[diarrhea]], [[vomiting]]
| |
| | |
| '''Dermatologic''': generalized rash/[[dermatoses]], [[itching]]
| |
| | |
| '''Central nervous system''': [[nervousness][]
| |
| | |
| '''Other''': [[hypokalemia]], elevated cholesterol/triglycerides
| |
| | |
| The following reactions were reported in less than 1%:
| |
| | |
| [[Depression]], [[insomnia]], [[dysuria]], [[numbness]]/tingling, elevated liver enzymes, AV block, elevated BUN, elevated creatinine, decreased [[hemoglobin]]/hematocrit
| |
| | |
| [[Hypoglycemia]] has been reported in association with Norpace administration (see Warnings).
| |
| | |
| Infrequent occurrences of reversible cholestatic [[jaundice]], fever, and respiratory difficulty have been reported in association with disopyramide therapy, as have rare instances of [[thrombocytopenia]], reversible [[agranulocytosis]], and [[gynecomastia]]. Some cases of LE ([[lupus erythematosus]]) symptoms have been reported; most cases occurred in patients who had been switched to disopyramide from procainamide following the development of LE symptoms. Rarely, acute psychosis has been reported following Norpace therapy, with prompt return to normal mental status when therapy was stopped. The physician should be aware of these possible reactions and should discontinue Norpace or Norpace CR therapy promptly if they occur.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = NORPACE (DISOPYRAMIDE PHOSPHATE) CAPSULE, GELATIN COATED [G.D. SEARLE LLC DIVISION OF PFIZER INC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=e2aa1642-d262-4520-bc6a-9fd3ad795677 | publisher = | date = | accessdate = 3 March 2014 }}</ref>
| |
| | |
| | |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| [[Category:Pyridines]]
| |
| [[Category:Sodium channel blockers]]
| |
| [[Category:Amides]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |